8-K: Panbela Therapeutics Announces Preferred Stock Issuance, Nasdaq Delisting, and CBOE Application

Panbela Therapeutics issued a single share of Series A Preferred Stock for $10, initiated a delisting from Nasdaq, and applied to list on the CBOE.

Summary

• Panbela Therapeutics entered into a Subscription and Investment Representation Agreement with Michael T. Cullen, the Chairman of the Board, on April 23, 2024.
• The company issued one share of Series A Preferred Stock to Mr. Cullen for $10 in cash.
• This preferred stock has 90,000,000 votes and will vote with common stock on any reverse stock split proposal.
• The preferred stock has no other voting rights, no rights to dividends or asset distribution, and can be redeemed for $10.
• Nasdaq filed a Form 25 to delist Panbela's common stock, effective ten days after filing.
• Panbela has applied to list its common stock on the US Equity Listings Tier II of the Chicago Board of Options Exchange (CBOE).
• The company intends to maintain its OTCQB listing under the symbol PBLA in the interim.
• A special meeting to vote on a reverse stock split has been postponed from May 3, 2024, to May 28, 2024, with a new record date of April 24, 2024.

Sentiment

Score: 3

Explanation: The document contains several negative events, including a Nasdaq delisting and a postponed shareholder meeting. While the company is pursuing a CBOE listing, the overall tone is concerning due to the delisting and the speculative nature of the company's future.

Positives

• The company is actively seeking a new exchange listing on the CBOE.
• The company is maintaining its OTCQB listing to ensure continued trading of its stock.

Negatives

• The company's common stock is being delisted from Nasdaq.
• The company has no revenue and is not profitable.
• The company's future is described as purely speculative.

Risks

• There is no guarantee that the CBOE listing application will be approved.
• There is no guarantee that a trading market will develop on the CBOE.
• The company may need to effect a reverse stock split to meet the minimum per share bid price requirement for the CBOE listing.
• The company faces risks related to obtaining additional funding, clinical trial progress, regulatory approvals, and market acceptance of its products.
• The company is subject to the risk of losing its entire investment.

Future Outlook

The company intends to pursue a listing on the CBOE and may need to effect a reverse stock split to meet listing requirements. The company is also focused on its clinical development programs and obtaining regulatory approvals.

Management Comments

• The Board of Directors has determined to hold the Special Meeting on May 28, 2024.
• The company intends to promptly prepare, file and mail a new proxy statement for the Special Meeting.

Industry Context

The delisting from Nasdaq and application to the CBOE is a significant event for a publicly traded biotechnology company. It reflects potential challenges in meeting Nasdaq's listing requirements and a strategic shift to a different exchange. This is not uncommon for smaller biotech companies that may struggle to maintain the required share price and market capitalization.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, often leading to delisting and a move to OTC markets or other exchanges.
• The issuance of preferred stock with specific voting rights related to a reverse stock split is a less common but not unheard of strategy to ensure the company can meet listing requirements.
• Companies like Agenus Inc. and Celldex Therapeutics have faced similar challenges with maintaining listing compliance, highlighting the competitive and volatile nature of the biotech industry.
• The move to the CBOE is a less common path for biotech companies, with most opting for the NYSE or Nasdaq, making it a unique situation for Panbela.

Related Party Transactions

• The issuance of preferred stock to Michael T. Cullen, the Chairman of the Board, is a related party transaction.

Stakeholder Impact

• Shareholders will be impacted by the delisting from Nasdaq and the potential reverse stock split.
• Shareholders will need to vote on the reverse stock split at the rescheduled special meeting.
• The company's employees may be affected by the uncertainty surrounding the company's listing status.

Next Steps

• The company will prepare and file a new proxy statement for the special meeting.
• The company will seek approval for its listing application on the CBOE.
• The company will maintain its OTCQB listing.

Key Dates

Keywords

Preferred Stock, Delisting, Nasdaq, CBOE, Reverse Stock Split, OTCQB, PBLA, Listing, Capital Raise, Biotechnology